APA to phase out pharma-sponsored CME, dinners

Share this article:

The American Psychiatric Association (APA) will put an end to industry-sponsored continuing medical education (CME) and meals served during its annual meetings, the association said Wednesday.

“It's important to differentiate CME from advertising…and promotional medical education,” said Nada Stotland, president of the APA. “There is data to indicate that goodies from pharmaceutical companies influence physicians. We consider [sponsored] presentations and fancy dinners to be goodies.”

The APA hosts the nation's largest meeting for psychiatrists each May, said Stotland, and industry sponsorships for that meeting vary, but usually account for over $1 million.

The plan will considerably reduce industry-sponsored CME and meals in 2009, said Stotland. The APA will eliminate all such sponsorships over the next two or three years, and possibly sooner, she said.

Accredited CME provides physicians with the credits needed to maintain a valid license according to state law requirements. Concerns over the potential influence or bias inherent in corporate-sponsored CME have prompted some medical schools, including Stanford University, the universities of Massachusetts, Pittsburgh, Kansas and others, to ban direct CME sponsorship entirely.

However, a Manhattan Research survey in February found that only 9% of surveyed physicians were opposed to pharma or device manufacturer-funded CME. Just 8% felt that sponsored CME programs they had attended were biased, according to the survey results. 

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...